Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events


selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients

Phase 1b trial is designed to evaluate safety, tolerability, and efficacy of potent Kv1.3 blocker in T-cell mediated autoimmunity – San Diego, CA, USA, and Munich, Germany – September 12, 2022 – selectION, Inc., a clinical-stage biopharmaceutical company developing novel…
Read More